Duncan, Lyn M.

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,005

Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma

Lian, C. G., Xu, Y., Ceol, C., Wu, F., Larson, A., Dresser, K., Xu, W., Tan, L., Hu, Y., Zhan, Q., et al. (2012) · Cell

Epigenetics and DNA MethylationChromatin Remodeling and Cancer

Cited by 789

HIF1α and HIF2α independently activate SRC to promote melanoma metastases

Hanna, S. C., Krishnan, B., Bailey, S. T., Moschos, S. J., Kuan, P.-F., Shimamura, T., Osborne, L. D., Siegel, M. B., Duncan, L. M., O’Brien, E. T., et al. (2013) · Journal of Clinical Investigation

Cancer, Hypoxia, and MetabolismMechanisms of cancer metastasis

Cited by 147

An Oncogenic Role for ETV1 in Melanoma

Jané-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010) · Cancer Research

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 115

Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study

Nazarian, R. M., Prieto, V. G., Elder, D. E., & Duncan, L. M. (2010) · Journal of Cutaneous Pathology

Cutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways

Cited by 65